Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Cantor Fitzgerald
Julphar
Queensland Health
Colorcon
Fuji
Medtronic
Harvard Business School
Accenture

Generated: May 21, 2018

DrugPatentWatch Database Preview

Indivior Inc Company Profile

« Back to Dashboard

What is the competitive landscape for INDIVIOR INC, and what generic alternatives to INDIVIOR INC drugs are available?

INDIVIOR INC has five approved drugs.

There are twelve US patents protecting INDIVIOR INC drugs.

There are one hundred and fifty-four patent family members on INDIVIOR INC drugs in twenty-seven countries.

Summary for Indivior Inc
International Patents:154
US Patents:12
Tradenames:4
Ingredients:3
NDAs:5
Patent Litigation for Indivior Inc: See patent lawsuits for Indivior Inc

Drugs and US Patents for Indivior Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-001 Aug 30, 2010 RX Yes No 8,603,514 ➤ Try a Free Trial Y ➤ Try a Free Trial
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-002 Aug 30, 2010 RX Yes No 9,687,454 ➤ Try a Free Trial Y ➤ Try a Free Trial
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-004 Aug 10, 2012 RX Yes Yes 9,687,454 ➤ Try a Free Trial Y ➤ Try a Free Trial
Indivior Inc SUBLOCADE buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 209819-001 Nov 29, 2017 RX Yes No 9,272,044 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for INDIVIOR INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sublingual Film 2 mg/0.5 mg and 8 mg/2 mg ➤ Subscribe 2012-10-15
➤ Subscribe Sulingual Film 12 mg/3 mg ➤ Subscribe 2014-03-26
➤ Subscribe Sublingual Film 4 mg/1 mg ➤ Subscribe 2013-05-14

Non-Orange Book US Patents for Indivior Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,910,031 Process for forming an ingestible thin film with non-self-aggregating uniform heterogeneity ➤ Try a Free Trial
7,425,292 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom ➤ Try a Free Trial
2,016,206,639 ➤ Try a Free Trial
9,108,340 Process for manufacturing a resulting multi-layer pharmaceutical film ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Chubb
Federal Trade Commission
Medtronic
AstraZeneca
Mallinckrodt
Teva
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.